Skip to main content
LYSOGENE logo

LYSOGENE — Investor Relations & Filings

Ticker · LYS ISIN · FR0013233475 LEI · 969500T64RILK1RD0852 PA Professional, scientific and technical activities
Open in API
Filings indexed 254 across all filing types
Latest filing 2020-02-11 Regulatory Filings
Country FR France
Listing PA LYS

About LYSOGENE

https://www.lysogene.com

Lysogene was a clinical-stage biotechnology company that specialized in the research and development of gene therapies for rare, inherited neurodegenerative diseases affecting the central nervous system (CNS). The company's approach focused on delivering a functional copy of a deficient gene directly to the brain to address the root cause of the targeted disorder. Its pipeline included investigational treatments for lysosomal storage diseases such as Sanfilippo syndrome type A (MPS IIIA) and GM1 gangliosidosis. Following clinical and financial challenges, the company initiated judicial liquidation proceedings in 2023.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press Release" and announces the company's participation and presentation schedule at an upcoming industry symposium (16th WORLDSymposium™ on Lysosomal Diseases). It provides key highlights about clinical trial progress and company background, which is characteristic of an Earnings Release (ER) or a general announcement. Since it is a press release announcing corporate activity (participation in a conference) rather than a formal regulatory filing like a 10-K, IR, or a specific financial outcome release (like DIV or ER), it fits best under the general regulatory announcement category, RNS, or potentially ER if it were tied to financial results. Given the content focuses on scientific presentations and corporate updates rather than quarterly financial figures, RNS (Regulatory Filings/General Announcement) is a strong candidate. However, press releases announcing key operational/scientific milestones often overlap with the intent of an Earnings Release (ER) if they are timely announcements of corporate progress. Since the definitions prioritize ER for initial financial results announcements, and this is a scientific/operational announcement, RNS is the most appropriate fallback for a general press release that doesn't fit a more specific category like DIV, CAP, or MANG. Given the structure and content (Press Release format, announcement of participation), RNS is the most suitable general regulatory/announcement category.
2020-02-11 English
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is explicitly titled "Press Release" and its primary content is announcing the company's "corporate agenda for 2020," which lists expected future communication dates for financial results (e.g., 2019 annual results, Q1 2020 sales, H1 2020 results) and operational milestones (e.g., AGM date, clinical trial updates). This document is not the actual financial report (like 10-K or IR), nor is it a transcript (CT) or a detailed presentation (IP). It is an announcement about future reporting schedules and key operational updates. Since it is a general announcement detailing future expected reports and events, it fits best under the category for announcing the publication of reports or general regulatory updates. Given the specific nature of announcing a calendar of future reports, the most appropriate classification is Report Publication Announcement (RPA), as it signals when other reports will be released. If RPA were not available, RNS would be the fallback, but RPA is more precise here.
2020-01-24 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "Calendrier financier 2020 de la société Lysogene" (2020 Financial Calendar for Lysogene) and is explicitly labeled as a "Communiqué de presse" (Press Release). It outlines future dates for reporting key financial metrics (revenue, cash position, annual results, quarterly results) and the Annual General Meeting. This type of announcement, which details the schedule for future corporate communications and results releases, best fits the category for announcing the publication of reports, rather than being the report itself (like 10-K or IR). Since it is an announcement about when reports will be released, the most appropriate classification is Report Publication Announcement (RPA). The document length (7089 chars) is substantial, but its primary function is scheduling future disclosures, not providing the detailed content of those disclosures.
2020-01-24 French
Franchissement de seuils
Director's Dealing Classification · 1% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing thresholds (Article L. 233-7 of the Commercial Code)'. This type of filing in France specifically reports changes in significant share ownership (crossing ownership thresholds) by an investor or entity. This directly corresponds to the definition of Major Shareholding Notification (MRQ), which covers 'Notification of changes in significant share ownership levels (crossing thresholds)'. The content details the Caisse des dépôts et consignations (CDC) crossing the 15% and 10% thresholds for LYSOGENE.
2020-01-22 French
Franchissement de seuils
Director's Dealing Classification · 1% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to "Declaration of crossing thresholds (Article L. 233-7 of the Commercial Code)". This French regulatory filing explicitly details changes in share ownership thresholds crossed by EPIC Bpifrance concerning the company LYSOGENE. This type of filing, which reports changes in significant share ownership, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is a formal regulatory declaration about shareholding changes, not a general announcement of a report (RPA/RNS) or a full annual/interim report.
2020-01-22 French
Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract
Capital/Financing Update Classification · 1% confidence The document is explicitly titled "ANNUAL REPORT OF THE LIQUIDITY CONTRACT SIGNED BY LYSOGENE WITH GILBERT DUPONT". It details the activity (buy/sell transactions) under a liquidity contract for the second semester of 2019, ending on December 31, 2019. This type of report, detailing transactions related to share stabilization or market making activities, is a specific type of regulatory disclosure concerning share capital or insider activity, but it is not a standard financial report (10-K, IR) or a general announcement (RPA/RNS). Since the document details transactions in the company's own shares (buy/sell activity under a contract), it most closely aligns with the definition of 'Transaction in Own Shares' (POS), which covers share repurchase/issuance activities, even if this specific context is a liquidity contract. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is a specific report on share transactions, making POS the most appropriate fit over the general RNS.
2020-01-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.